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Introduction
The human epidermal growth factor receptor (HER)-family is one of 20 subfamilies of human receptor tyrosine kinases (RTKs) comprising epidermal growth factor receptor (EGFR) (ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Many cancers are driven by HER-family dependencies where signal transduction pathways of the HER-family receptors are deregulated leading to increased proliferation and escape from apoptosis [1] [2] [3] .
EGFR is one of the most studied HER-family receptors and a recognized key oncogenic driver in many epithelial cancers. Upon activation by ligands such as epidermal growth factor (EGF) two monomeric EGFRs dimerize to form an actively signaling complex. EGFR also associates in heterodimers with other RTKs, such as HER2 and HER3 [2] , [4] . It is well known that heterodimerization of and cross-talk between HER-family receptors play an important role in primary and acquired resistance to targeted treatments [5] [6] [7] .
Furthermore, accumulating evidence suggests that dimerization is not always ligand-dependent and that when EGFR is overexpressed, a significant fraction of receptors exists in preformed homo-and heterodimers [8] [9] [10] . Also, there is a correlation between overexpression of EGFR and activation of downstream signaling molecules such as AKT and ERK1/2 [11] , suggesting that the preformed dimers are actively signaling. This phenomenon is also known for other RTKs such as HER2 and MET [12] , [13] .
As mentioned above, EGFR forms heterodimers with both HER2 and HER3, with HER2 being the preferred heterodimerization partner for the other HER-family members [2] , [14] , [15] . Furthermore, no ligand for HER2 has been identified and HER2 activation therefore requires heterodimerization with other receptors to become ligand-activated. HER3 is activated upon binding of heregulin (neuregulin), but since HER3 contains an impaired tyrosine kinase, the receptor can most potently signal in heterodimers [16] , [17] . Upon EGF-induced activation of EGFR homodimers, the receptors undergo fast internalization and degradation compared to ligand-induced internalization of other HER-family members [18] [19] [20] . In this regard, it has been shown that EGFR in heterodimers with HER2 or HER3, and overexpression of for instance HER2 results in prolonged and enhanced signaling, through increased recycling and internalization compared to EGFR in homodimers [21] [22] [23] .
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This article is protected by copyright. All rights reserved. (Perjeta ® ) targeting HER2 [24] . While no HER3 targeting antibodies have yet reached clinical approval, the fully human mAb MM-121 (Seribantumab) is currently being evaluated in late clinical trials [25] , [26] .
However, acquired resistance towards single receptor targeting treatments greatly limits the therapeutic potential of single HER-targeting therapies. Mechanisms of resistance toward single HER-family targeting mAbs include receptor mutations, increased ligand production, compensatory receptor up-regulation, switch in receptor dependency, and increased receptor cross-interactions by heterodimerization [6] . Specifically with regards to cetuximab resistance, mechanisms such as increased EGFR expression and co-activation of other RTKs through heterodimerization with EGFR has been observed [27] . Resistance mechanisms to trastuzumab treatment also include increased EGFR expression, activation of EGFR-HER2 heterodimers, and increased levels of EGFR and HER3 ligands [28] , [29] .
It has been shown that mixtures of mAbs targeting a single HER-family member have superior inhibitory efficacy when it comes to cell growth, down-regulation of single receptors and heterodimers, and decreased downstream signaling compared to a single mAb targeting the same receptor [30] [31] [32] [33] [34] . Furthermore, it has been shown that resistance toward single targeting mAbs as a result of switch in receptor dependency and receptor heterodimerization can be overcome by targeting the activated receptor [27] . For example cetuximab resistances, due to ligand-induced activation of HER3 and prosurvival pathways, can be abrogated by treatment with MM-121 or dual EGFR-HER2 targeting [26] , [35] , [36] . Also, increased expression of HER3 due to pertuzumab treatment can be abrogated by targeting HER3 [37] . 
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Materials and Methods

Cell lines
PK-1 and OVCAR-8 cell lines were obtained from RIKEN Cell Bank and National Cancer Institute, respectively and grown for limited numbers of passages in RPMI1640+10% Fetal Bovine Serum (FBS)+1%
Penicillin/Streptomycin (Life Technologies) at 37°C, 5% CO 2 , and serum starved 24-48 hours prior to experiments. All cell lines were routinely tested for mycoplasma infection and cell line authenticity was documented by Human Cell Line Authentication (LGC Standards).
Therapeutic antibodies
The six antibodies used for the 2-mAb mixtures and Pan-HER were generated as described elsewhere [38] .
Cetuximab (Erbitux ® ) and trastuzumab (Herceptin ® ) were obtained from Merck KGaA and Roche, respectively. Analogues of pertuzumab and MM-121 were generated in house and tested, along with a mAb binding non-human IgG used as negative control, as previously specified [34] , [38] .
Detection of cell surface expressed receptors
Flow cytometry was used to quantify surface expressions of EGFR, HER2, and HER3 in cancer cell lines 
Western blot analysis
Effects of antibody treatments on total and phospho-protein levels were investigated by Western blot analysis. Primary antibodies: Rabbbit anti-EGFR, rabbit anti-HER2, rabbit anti-HER3 (Cell Signaling Technology, clone #: D38B1, 29D8, and D22C5), mouse anti-HER3 (Millipore, clone #: 2F12), rabbit anti-AKT, rabbit anti-pAKT (Ser473), rabbit anti-ERK1/2, rabbit anti-pERK1/2 (Thr202/204), and rabbit anti-β-actin (Cell Signaling Technology, clone #: D9E, D13.14.4E, and 13E5) diluted in Odyssey Blocking Buffer (LI-COR Biosciences) were used for detection, and membranes were scanned on Odyssey Scanner (LI-COR Biosciences) using Odyssey IR Imaging System (LI-COR Biosciences).
Duolink in situ proximity ligation assay
Duolink proximity ligation assay (PLA) was used for detection, quantification, and visualization of EGFR homo-and heterodimers, using EGFR, HER2, and HER3 detection antibodies generated as described elsewhere [38] . PLUS and MINUS PLA probes were made from these antibodies according to the 
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Detection of labelled EGF to PK-1 cells
5,000 PK-1 cells/well were plated in 2% FBS 48h prior to 30minutes of Pan-HER treatment and stimulation with 2ug/mL Alexa-647 labelled EGF (Thermo Fisher Scientifc) for 3min at 4°C to limit ligand-induced internalization. Cells were fixed, permeabilized, and blocked as described above prior to staining with FITClabelled anti-EGFR antibody (Abcam, Clone ICR10) for 1h. Cytosols and nuclei were stained with Cell Mask Blue and Hoechst (Life Technologies) followed by confocal microscopy analysis.
Co-Immunoprecipitation
Indirect Co-IP with streptavidin-conjugated beads was performed according to manufacturers instructions (Thermo Scientific), using 2 mg total protein from each lysate sample and biotinylated capture or isotype control antibody (R&D Systems and Cell Signaling Technology, clone MOPC-21), and incubated for two hours with tilting at room temperature. 0.5 mg beads per sample were prewashed prior to incubation with Ab-antigen samples for one hour with tilting at room temperature. Finally, samples were washed, incubated in low pH Elution Buffer for 5 minutes at room temperature, and subjected to Western blot analysis.
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Selection and characterization of HER-dependent cancer cell lines for studying EGFR dimerization
Seeking to evaluate the effect of Pan-HER on EGFR homo-and heterodimerization, we aimed to identify EGFR high expressing cancer cell lines with sensitivity to more than one HER-targeted therapeutic mAb, because such models could be expected to be driven by HER-family heterodimerization.
15 cancer cell lines sensitive to Pan-HER treatment [38] (and data not shown) were screened for total and surface expression levels of EGFR, HER2, and HER3 by Western blot analysis and flow cytometry, respectively. The 15 cell lines displayed highly varying receptor levels, even though the majority expressed rather high levels of EGFR (Fig. 1A) . Based on the protein levels in Fig. 1A and a previous screen of HERdependence [38] , two cell lines (PK-1 and OVCAR-8) were selected for studying sensitivity to single HERtargeting and Pan-HER. Both PK-1 and OVCAR-8 expressed very high cell surface levels of EGFR and both cell lines expressed low but detectable levels of HER2 (Fig. 1B) . This effect of Pan-HER (Suppl. Fig. 1 ) and the other HER-targeting mAbs demonstrates that targeting of the receptors with more than one antibody effectively decreases proliferation, and that more than one HERfamily member contributes to the growth of both cell lines, which were therefore considered suitable in vitro models for studying alterations in HER-dimerization patterns upon Pan-HER treatment.
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Treatment with Pan-HER has previously been reported to cause simultaneous down-regulation of EGFR, HER2, and HER3 [38] , so in order to evaluate effect on downstream signaling, the effect of Pan-HER and single targeting mAbs on total HER-family receptor levels and phosphorylation levels of the major downstream signaling molecules AKT and ERK1/2 was investigated in both cell lines. The mixtures targeting single receptors caused down-modulation of their respective target, while Pan-HER simultaneously reduced the protein levels of all three receptors (Fig. 2B ). Cetuximab and pertuzumab treatment did not alter the receptor levels, however, trastuzumab and MM-121 were able to decrease the HER2 and HER3 levels, binding and cross-reactivity to EGFR, HER2, and HER3 [34] , [39] , [40] (Suppl. Fig. 2 ).
EGFR is known to associate in preformed homodimers in absence of ligand [8] [9] [10] and since PK-1 and OVCAR-8 both express high levels of EGFR, the level of EGFR homodimers in these cell lines was investigated using PLA. In contrast to cetuximab, which did not alter the EGFR homodimer level, both the EGFR-targeting mAb mixture and Pan-HER significantly decreased the basal EGFR homodimer level in both PK-1 and OVCAR-8 upon 24 hours of treatment (p< 0.001, p< 0.01, and p< 0.05) (Fig. 3) . These results correlate with the decrease in total EGFR levels detected by Western blot analysis upon treatment with the EGFR-targeting mAb mixture and Pan-HER but not upon cetuximab treatment (Fig. 2B) . The decrease in homodimers is therefore likely due to receptor degradation. This is further supported by the fact that no significant receptor degradation and no change in basal EGFR homodimer and EGFR-HER2 heterodimer levels were observed upon one hour treatments (data not shown). Furthermore, it could be speculated that treatment with single mAbs targeting other HER-family members could push the dimerization balance towards an increase in EGFR homodimers. However, treatment with trastuzumab, pertuzumab, and MM-121 did not affect EGFR homodimerization levels (data not shown).
Pan-HER down-regulates basal EGFR heterodimer levels in PK-1 and OVCAR-8 cells
EGFR has been shown to associate in preformed heterodimers with HER2 or HER3 [8] , [9] , and therefore the basal levels of HER-family heterodimers in PK-1 and OVCAR-8 was also investigated after treatment (Fig. 4) . Collectively, the results in 
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the EGFR-targeting mAb mixture reduced both EGFR-HER2 and EGFR-HER3 levels in both cell lines the HER2-and HER3-targeting mAb mixtures did not significantly alter the EGFR-HER2 and EGFR-HER3
dimer levels in OVCAR-8, respectively, despite the fact that the receptors are being degraded (Fig. 2B) .
Furthermore, trastuzumab and MM-121 treatments resulted in degradation of HER2 in PK-1 and OVCAR-8 cells and HER3 in OVCAR-8 cells, respectively (Fig. 2B ), but neither treatment altered the EGFR-HER2
and EGFR-HER3 heterodimer levels (Fig. 4) . This indicates that targeting of more than one receptor in the dimer is more likely to succesfully down-regulate preformed HER-family dimer levels, and that Pan-HER has the potential to prevent cancer cells from evading treatment by switching HER-family dependency.
Pan-HER prevents EGF-induced changes in EGFR dimerization in PK-1 cells
Increased EGFR expression, increased EGFR-HER2 heterodimerization, and increased levels of EGF all play a role in acquired resistance toward cetuximab and trastuzumab [27] , [28] . Therefore, it was of interest to investigate the effect of treatment on ligand stimulation and ligand-induced HER-family dimerizations.
This was done by investigating the ability of Pan-HER to interfere with EGF binding to EGFR and by studying the EGFR homo-and EGFR-HER2 heterodimerization levels upon treatment with single targeting mAbs, mixtures, and Pan-HER for 24 hours followed by 15 minutes of EGF stimulation in PK-1 cells. The PLA signals were normalized to total EGFR protein levels as determined by western blot analyies after 24 hours of treatment, to exclude the effect of protein degradation on the PLA dimerization signal.
In Figure 5A , the immunofluorescence stainings showed that Pan-HER effectively blocks EGF binding to EGFR, thereby possibly preventing EGF from inducing changes in EGFR dimerization levels (Fig. 5A) .
Furthermore, using PLA it was shown that 15 minutes of EGF stimulation lowered the basal EGFR dimer levels in PK-1, likely due to ligand-induced receptor activation and internalization resulting in decreased detection by PLA. However, cetuximab, the EGFR-targeting mAb mixture, and Pan-HER maintained EGFR dimer levels at baseline levels regardless of EGF stimulation (Fig. 5B) supporting the result in Figure 5A , that the EGFR-targeting mAbs of Pan-HER interfer with EGF-induced EGFR dimer dynamics. On the other
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14 hand, none of the other single mAbs inhibited the EGF-induced decrease in the dimer levels, and neither did the HER2-targeting mAb mixture shown by an even larger decrease in the detected dimer level (Fig. 5B) .
To confirm and support these results, Co-IP for detection of EGFR homo-and EGFR-HER2 heterodimers was performed on whole cell PK-1 lysates. As shown in Fig. 5C 
Discussion
Previous studies have shown that increased EGFR expression and activation of HER2 and HER3 through heterodimerization with EGFR are involved in acquired resistance towards cetuximab and trastuzumab [27] , [28] . Here we demonstrate the potential of the antibody mixture Pan-HER to overcome such resistance, since
Pan-HER was found to down-regulate both total HER-family receptor levels, basal EGFR homo-and heterodimer levels, and prevent EGF-induced changes in EGFR dimerization in two EGFR overexpressing cell lines.
Pan-HER and the single HER-targeting mAb mixtures were shown to decrease the total receptor levels more effectively than the single mAbs in both PK-1 and OVCAR-8 cells (Fig. 2B ). It has previously been shown that two antibodies targeting a single HER-family receptor more potently down-regulate the receptors than a single mAb targeting the same receptor [30] [31] [32] [33] [34] , [38] . In the current studies all treatments were performed at targeted [31] . Furthermore, compensatory receptor up-regulation was observed upon treatment with some of the single receptor targeting mAbs and mixtures (Fig. 2B) , while the ability of Pan-HER to simultaneously decrease the level of EGFR, HER2, and HER3 prevents compensatory HER-family receptor up-regulation as a resistance mechanism.
The effect of mAb mixtures targeting more than one HER-family receptor on heterodimerization has only received limited focus so far [32] , [41] , [42] . 
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EGFR-HER2 heterodimerization in the presence of EGF [32] is consistent with the effect of Pan-HER shown in Fig. 5 , and the ability of cetuximab plus trastuzumab to down-regulate basal EGFR-HER2 heterodimers is consistent with the effect of Pan-HER shown in Fig. 4 [41] , [42] . Common for these results is also that the single mAbs have almost no effect by themselves compared to the multitargeting when it comes to altering the HER-family dimerization levels.
The preformed EGFR homo-and heterodimers may drive resistance development in two ways. First, the preformed dimers may be able to potently signal in a ligand-independent manner when overexpressed, as is the case with HER2 and MET overexpression [12] , [13] , or secondly they might be positioned in dormant receptor complexes which will be activated upon increased ligand production, which is also a documented resistance mechanism [26] , [28] , [43] . In both cases, the ability of Pan-HER (but not the single mAbs) to remove preformed EGFR homo-and heterodimers, might reduce the risk of development of such resistances.
Phosphorylation of both AKT and ERK1/2 was down-regulated upon treatment with Pan-HER (Fig. 2B ), indicating inhibition of both signaling pathways. In contrast, the effect of the single mAbs on downstream signaling varied in the two cell lines. The pAKT level was decreased upon treatment with HER3-targeting in both cell lines, correlating with the fact that HER3 activates AKT. Furthermore, the pERK1/2 level was decreased by treatment with EGFR-targeting in PK-1 and HER3-targeting in OVCAR-8, the latter indicating that signaling through EGFR-HER3 heterodimers is inhibited, decreasing the activation of ERK1/2 [2] . Even though trastuzumab treatment resulted in down-regulation of total HER2 levels in both cell lines, neither pAKT nor pERK1/2 levels were altered (Fig. 2 ).
Pertuzumab has previously been shown to block HRG-induced dimerization of HER2 and HER3 and also down-regulate basal HER2-HER3 dimer levels in HER2-high expressing cancer cells [44] , [45] .
Furthermore, pertuzumab has been shown to disrupt EGFR-HER2 heterodimers and push the dimer distribution toward EGFR homodimerization when stimulated with EGF [46] , [47] . Surprisingly, we found that pertuzumab was neither able to down-regulate basal EGFR-HER2 dimer levels, nor prevent EGFinduced down-regulation of EGFR-HER2 heterodimers using PLA. However, this might be explained by the 
relatively low HER2 expression in these two cell lines, as pertuzumab might have a different effect on dimer distribution in HER2 overexpressing and/or amplified cell lines. Furthermore, cetuximab has been shown by others to slightly reduce both basal and EGF-induced EGFR-HER2 dimerization [42] . However, only the ability of cetuximab to block EGF-induced down-regulation of EGFR dimers was observed in this study.
This is in line with the finding that cetuximab partially blocks the EGF binding site and locks EGFR in its closed conformation [48] .
The effect of EGF on EGFR dimerization was investigated using two different assays: PLA and Co-IP.
Using PLA, 15 minutes of EGF stimulation resulted in a decrease in EGFR dimer levels after normalization to total EGFR levels, indicating rapid internalization of EGFR dimers in line with previous reports by others [18] [19] [20] . Co-IP-based analysis of the effect of EGF on whole cell EGFR-dimer levels demonstrated that 15 minutes of EGF stimulation resulted in an increase in EGFR homo and heterodimer levels, correlating with previous use of Co-IP to detect EGFR-HER2 dimers upon EGF stimulation [47] . This difference in the effect of EGF might be explained by differences in the two assays. For example, if PLA primarily detects dimers at the cell surface level, the loss of EGFR dimer signals would be explained by internalization but not degradation of the dimers, which is expected to take more than 15 minutes. This explains why an increase in EGFR dimer levels was observed using Co-IP, which detects both intra-and extracellular dimer complexes.
Therefore, we decided to normalize the EGFR dimer levels with and without EGF stimulation to the total EGFR levels, to study the effect of antibody treatments on EGFR dimerization dynamics while excluding the effect of receptor degradation. This showed that, Pan-HER, the EGFR targeting mAb mixture, and cetuximab were all able to prevent the EGF-induced dimer formation. This was further supported by the fact that Pan-HER was found to completely block EGF binding to EGFR (Fig. 5A) . However, it is important to notice that even though all three treatments effectively blocked EGF, only the EGFR targeting antibodies of Pan-HER resulted in single receptor and dimer degradation.
In summary, the data presented here demonstrate superiority of the novel antibody mixture Pan-HER compared to single reference mAbs with regards to inhibition of proliferation, enhanced receptor degradation, and down-regulation of EGFR homo-and heterodimers with and without ligand stimulation.
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The results imply that Pan-HER by these means will be able to overcome acquired resistance that cannot be sufficiently prevented by single targeting mAbs, whether the resistance mechanism is based on increased expression of HER-family receptor, switches in HER-family dependency and dimerization patterns, or increased ligand production. Our data support clinical evaluation of Pan-HER in patients with HER-family dependent epithelial tumors.
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